<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001693" GROUP_ID="NEONATAL" ID="534399091720454909" MERGED_FROM="" MODIFIED="2008-11-12 18:53:32 +0100" MODIFIED_BY="Diane Haughton" NOTES="&lt;p&gt;Short title (no longer in use): Peripheral retinal ablation for ROP&lt;/p&gt;&lt;p&gt;sent for update Oct/03&lt;/p&gt;&lt;p&gt;sent to Loni for update Dec 5/06&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-11-12 12:52:08 -0500" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="001" REVMAN_SUB_VERSION="5.0.17 beta" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2008-11-12 18:53:32 +0100" MODIFIED_BY="Diane Haughton">
<TITLE>Peripheral retinal ablation for threshold retinopathy of prematurity in preterm infants</TITLE>
<CONTACT MODIFIED="2008-11-12 18:53:32 +0100" MODIFIED_BY="Diane Haughton"><PERSON ID="18243CAD82E26AA201A256C7570AA916" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Chad</FIRST_NAME><LAST_NAME>Andersen</LAST_NAME><POSITION>Consultant Neonatologist</POSITION><EMAIL_1>chad.andersen@cywhs.sa.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Perinatal Medicine</DEPARTMENT><ORGANISATION>Children's Youth and Women's Health Service</ORGANISATION><ADDRESS_1>72 King William Road</ADDRESS_1><CITY>North Adelaide</CITY><ZIP>5006</ZIP><REGION>SA</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>61 08 81617631</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-12 18:53:32 +0100" MODIFIED_BY="Diane Haughton"><PERSON ID="18243CAD82E26AA201A256C7570AA916" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Chad</FIRST_NAME><LAST_NAME>Andersen</LAST_NAME><POSITION>Consultant Neonatologist</POSITION><EMAIL_1>chad.andersen@cywhs.sa.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Perinatal Medicine</DEPARTMENT><ORGANISATION>Children's Youth and Women's Health Service</ORGANISATION><ADDRESS_1>72 King William Road</ADDRESS_1><CITY>North Adelaide</CITY><ZIP>5006</ZIP><REGION>SA</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>61 08 81617631</PHONE_1></ADDRESS></PERSON><PERSON ID="6698" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Dale</FIRST_NAME><LAST_NAME>Phelps</LAST_NAME><EMAIL_1>dale_phelps@urmc.rochester.edu</EMAIL_1><ADDRESS><DEPARTMENT>Pediatrics and Ophthalmology</DEPARTMENT><ORGANISATION>University of Rochester</ORGANISATION><ADDRESS_2>Box 651, Pediatrics, 601 Elmwood Ave, Rochester</ADDRESS_2><CITY>New York</CITY><REGION>14642</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 716 275 5884</PHONE_1><FAX_1>+1 716 461 3614</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-05-05 02:06:23 -0400" MODIFIED_BY="Chad Andersen">
<UP_TO_DATE>
<DATE DAY="10" MONTH="5" YEAR="1999"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="10" MONTH="5" YEAR="1999"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="10" MONTH="5" YEAR="2000"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="1999"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="7" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="10" MONTH="5" YEAR="1999"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-12 12:46:36 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-11-12 12:46:36 -0500" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-04-07 15:44:35 -0400" MODIFIED_BY="[Empty name]">Peripheral retinal ablation for threshold retinopathy of prematurity in preterm infants</TITLE>
<SUMMARY_BODY MODIFIED="2008-11-12 12:46:36 -0500" MODIFIED_BY="[Empty name]">
<P>Advances in perinatal medicine have led to increased survival of extremely low birth weight infants and an increase in the incidence of retinopathy of prematurity (ROP). This is a vascular proliferative disorder of the immature retina in premature infants that can result in impairment of vision and a high (&gt; 47%) chance of blindness if untreated (threshold ROP). Normally the retina has a complete system of blood vessels by 40 weeks. Injury to the developing retinal capillaries occurring before or during birth and in the days following delivery stimulates new vascularization, which is the observable retinopathy. This can result in successful revascularization of the retina (regression of the ROP) or progression to neovascular membranes in the vitreous, subsequent scarring and retinal detachment. The incidence and severity of retinopathy is inversely related to gestational age. Treatment involves removal (ablation) of the part of the retina without blood vessels to preserve central macula vision. Cryoablation and laser techniques are used. The review authors identified two randomised trials involving 291 and 28 premature infants with threshold ROP, reported in the 1980s. Both used cryotherapy for peripheral retinal ablation, reducing the incidence of adverse ophthalmic outcomes. Unfavorable retinal structure at less than 12 months and in early childhood at 5½ years (234 infants) was reduced by some 18 to 20%. Therefore, the number of eyes with threshold ROP needed to treat (NNT) to avoid one unfavorable outcome is around five. The risk of poor visual acuity in early childhood was reduced from 63 to 51% (NNT 8). </P>
<P>The advantage of retinal ablation in these eyes outweighs short term morbidity associated with the therapy. This includes an increase incidence of apnoea and bradycardia both during the procedure and in the following one to three days. The visual fields in sighted eyes were slightly smaller in the group receiving cryoablation as compared to the control group. It is important to note that compared to normal, eyes with ROP that spontaneously recovered also had a reduction in visual field. At this stage, long term outcomes remain unknown.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>This section is under preparation and will be included in the next issue.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>In premature infants with threshold retinopathy of prematurity (ROP) does peripheral retinal ablation, by any means, reduce the incidence of adverse ophthalmic outcome?</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>The standard search strategy of the Cochrane Neonatal Review Group was used. This included a search of the Cochrane Neonatal Group Register of Clinical Trials, MEDLINE, EMBASE, previous reviews including cross references, abstracts from pediatric and ophthalmologic meetings, letters and expert informants. Search terms included "Retinopathy of Prematurity" [MeSH Terms], "Retrolental Fibroplasia" [All Fields] and "Lightcoagulation" [All Fields] or "Cryosurgery" [All Fields]. In addition, a personal bibliographic database was used as a cross-reference.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All trials in human premature infants with threshold ROP utilizing random or quasi random allocation to either peripheral retinal ablation of the avascular retina, by any means, or concurrent control group with independent outcome assessment were initially selected for review. Following methodologic review, only studies using random allocation were selected for data extraction.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Relevance and validity were assessed by the two authors and consensus reached. Each author extracted clinical outcomes from valid reports independently. Data analysis was conducted according to the standards of the Cochrane Neonatal Review Group.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Two randomised trials were identified. Data from these studies show that peripheral retinal ablation reduces the risk of (1) early unfavorable retinal structure from 47.9% to 28.1% (absolute risk reduction 19.8% [95% CI 27.9 - 11.8%]), (2) unfavorable retinal structure in early childhood from 44.3% to 26.3% (absolute risk reduction 18% [95% CI 27.0 - 9.1%]) and (3) unfavorable visual acuity in early childhood from 63% to 50.6% (absolute risk reduction 12.2% [95% CI 21.2 - 3.1]). In addition, visual fields in sighted eyes were slightly smaller in the treated (51.3° ± 11.8°) group as compared to the control (58.2°± 14.5°) group.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Peripheral retinal ablation reduces the incidence of adverse ophthalmic outcome in premature infants with threshold ROP. In sighted eyes, peripheral retinal ablation may reduce the size of the visual field. At this stage, long term outcomes remain unknown.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Along with advances in perinatal medicine and the associated increased survival of extremely low birth weight infants has been a rise in the incidence of retinopathy of prematurity (ROP). As a vascular proliferative disorder of the immature retina in premature infants, ROP has both immediate and long-term complications. In the acute stages retinopathy can progress and threaten vision. In the long-term, even after regression, retinopathy can lead to acuity defects, refractive errors (especially high myopia) and gaze abnormalities. As such, it is a life long disorder that has a significant impact on the neurodevelopmental progress of premature infants.<BR/> <BR/>Normally, the nasal and temporal retina are usually completely vascularised, to the ora serrata, by 36 and 40 weeks respectively. However, if damage occurs to the retinal capillaries during vascularisation then delay in vascularisation results. The pathophysiology in understood to start with injury to the developing retinal capillaries. This could potentially occur before or during birth, but is thought to primarily occur in the days following delivery. Once the developing vessels have been damaged, it is hypothesized that the retina responds with the production of vascular growth factors stimulating neovascularization, which is the observable retinopathy. This may result in successful revascularization of the retina (regression of the ROP), or in progression to neovascular membranes in the vitreous and subsequent scarring (cicatrix) and retinal detachment. Recent research suggests that vascular endothelial cell growth factor (VEGF) is one of the most important growth factors involved in this process (<LINK REF="REF-Aiello-1996" TYPE="REFERENCE">Aiello 1996</LINK>, <LINK REF="REF-Provis-1997" TYPE="REFERENCE">Provis 1997</LINK>). </P>
<P>It is clear that the incidence and severity of retinopathy is inversely related to gestational age. Whilst the majority of infants less than 30 weeks gestational age will develop some form of retinopathy, in most cases it will regress spontaneously. Some infants, however, will develop progressive retinopathy which threatens vision. </P>
<P>Following a series of consensus meetings in 1984, ROP was newly classified according to the location (zone), extent (clock hours of disease), severity (stage) and presence or absence of plus disease, which represents vascular decompensation manifest as vessel dilatation and tortuosity (ICCROP 1984). This included the description of 'threshold' ROP, a prognostically relevant level of disease severity at which the risk of blindness in untreated eyes is greater than 47% (CRYO- ROP 1988).</P>
<P>Treatment of established 'threshold' ROP was introduced in order to prevent the high risk of blindness in affected eyes. This involves ablation of the peripheral avascular retina, thus preserving central macula vision. Initially transscleral cryoablation was used, as it was technically easier in infants with hazy vitreous. Subsequently, both photocoagulation and cryoablation have been used to destroy the avascular immature retina thought to be responsible for the angiogenic growth factors that drive the neovascularisation of the ROP. </P>
<P>The purpose of this review is to systematically evaluate the effect of peripheral avascular retinal ablation, by any means, on the incidence of adverse ophthalmic outcome in premature infants with threshold ROP.</P>
</BACKGROUND>
<OBJECTIVES>
<P>The objective of this review is to answer the question "In premature infants with threshold ROP does peripheral retinal ablation, by any means, reduce the incidence of adverse ophthalmic outcomes?"</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Relevant:<BR/>Human, premature infants with threshold ROP.<BR/>Peripheral retinal ablation of the avascular retina by any means.<BR/>Concurrent control group.<BR/>Outcomes identified and recorded systematically</P>
<P>Valid: In addition to relevant:<BR/>Randomised assignment<BR/>Concealment of group assignment prior to randomisation<BR/>Independent outcome assessment with masking of treatment allocation where possible.<BR/>Follow up rate &gt; 80%.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Human preterm infants with "Threshold ROP".</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Ablation of the peripheral avascular retina by any means including cryotherapy, laser diode, laser argon, xenon arc photocoagulation. Reports using treatment to the proliferating ridge were not included.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>1. Early unfavorable retinal structure, assessed at less than 12 months, defined as:<BR/>(1) a posterior retinal fold (usually involving the macula) or <BR/>(2) a retinal detachment involving zone 1 of the posterior pole or<BR/>(3) retrolental tissue or mass obscuring the view of the posterior pole. </P>
<P>2. Early childhood unfavorable retinal structure, assessed at 4 to 6 years, defined as:<BR/>(1) ROP stage 4B or greater, <BR/>(2) obstructed view of macula from <BR/>(a) partial or complete cataract,<BR/>(b) partial retrolental membrane or<BR/>(c) partial or complete corneal opacity (owing to ROP),<BR/>(3) enucleation from all causes.</P>
<P>3. Early childhood unfavorable visual acuity, assessed at 4 to 6 years, defined as absence of vision or Snellen visual acuity of 20/200 or worse.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>Multiple sources were searched with the following used as MeSH headings and/or keywords: [Retinopathy of Prematurity], [Retrolental Fibroplasia] and [Lightcoagulation] or [Cryosurgery].</P>
<P>Databases searched included the Cochrane Neonatal Review Group Register of Clinical Trials, MEDLINE, EMBASE and the Oxford Database of Perinatal Trials. In addition to the databases, review articles, abstracts from pediatric and ophthalmologic meetings through 1998, letters and expert informants were used.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>The standard methods of the Cochrane Collaboration for conducting a systematic review were used (Cochrane Handbook).</P>
<P>The initial comprehensive search yielded approximately 500 articles. These articles were screened independently by both authors by title and abstract into two groups, not relevant (by selection criteria) and possibly relevant (112). There was very strong agreement between the authors.<BR/>Photocopies of the possibly relevant articles were provided to two independent reviewers in order to determine the true relevance of the article and the methodology used in the study. Fifteen articles were considered relevant; twenty-six others were editorials, letters (without data), retrospective reviews and case series without controls; sixty were not relevant and six required further assessment (foreign language). <BR/>Four relevant studies contained in twenty citations were identified. Photocopies of the citations were provided to both reviewers who independently determined the methods used in the study. Methods were evaluated for concealment of randomisation and intervention, masking of outcome assessment where possible and completeness of follow up. Two studies were excluded; one did not use random allocation and the other used ablation to the peripheral avascular retina as well as the demarcation line, which is no longer recommended therapy (<LINK REF="STD-Harris-1976" TYPE="STUDY">Harris 1976</LINK>). <BR/>For the two remaining randomised studies, both reviewers independently extracted the data. As the unit of randomisation is the eye and not the infant, data extraction was based on results in eyes rather than in infants. </P>
<P>Relative risk and absolute risk reduction were examined for each study and for pooled data.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>1. Multicenter Trial of Cryotherapy for Retinopathy of Prematurity 1988(<LINK REF="STD-CRYO_x002d_ROP-1988" TYPE="STUDY">CRYO-ROP 1988</LINK>): Included<BR/>In this study, 291 infants with threshold ROP (defined as at least five contiguous or eight cumulative 30° sectors (clock hours) of stage 3+ ROP in zone 1 or zone 2) were enrolled at 23 centres. Eyes with 'threshold' ROP were randomised to either treatment with cryotherapy or control (no therapy). Random assignment was centralised with a telephone call to the coordinating centre. If the disease was bilateral, one eye was randomised and the fellow eye received the alternate therapy. If the disease was unilateral, only that eye was randomised. For the eyes allocated to treatment, cryotherapy was undertaken within 72 hours of randomisation. The results from this large study have been reported in multiple publications at various intervals of follow up from 3 months to 5½ years (see multiple citations in reference list). The current analysis was restricted to results at 3 months (Arch Ophthalmol 1990;108:195-204) and 5½ years (Arch Ophthalmol 1996;114:417-424) for simplicity. The results at 3½ years (Arch Ophthalmol 1993) were similar. At 3 and 12 months after randomisation, fundus examination was performed independently by two ophthalmologists and stereoscopic photographs of the retina were taken. Retinal scars from cryotherapy were obscured on the photographs before assessment at the central reading centre. 234 infants were available for follow up at 5½ years (36 died and 21 lost to follow up). Structural outcome was assessed by a "study certified ophthalmologist" and functional outcome was determined using Snellen visual acuity scores. </P>
<P>2. Tasman, et al 1985 (Tasman 1985): Included<BR/>In this study, 28 infants with bilateral threshold ROP (stage III ROP and plus disease) were randomised to cryotherapy or control (no therapy). One eye was randomised to treatment or control and the fellow eye received the alternate therapy. Treatment occurred within 48 hours of randomisation. Infants with unilateral disease were excluded. Outcome assessment was determined within 14 days of therapy as satisfactory or unsatisfactory defined as persistence of plus disease and continued development of extraretinal fibrovascular proliferation leading to Stage 4 ROP. It is not clear if treatment allocation was masked or if outcome assessment was independent. </P>
<P>3. Harris, 1976 (<LINK REF="STD-Harris-1976" TYPE="STUDY">Harris 1976</LINK>): Excluded from analysis<BR/>In this study 10 premature infants with bilateral ROP were randomised to either retinal ablation or control. One eye was randomised using a coin toss and the fellow eye received the alternate therapy. Treatment consisted of either "direct xenon photocoagulation to the advancing fibrovascular margin, transscleral cryocoagulation of this margin, transscleral cryocoagulation of the margin plus cryocoagulation of the anterior avascular retina or delimiting photocoagulation of the normal retina immediately behind the vascularised ridge". Outcomes were not individually reported for the twenty eyes as the authors intended to report only long term outcomes many years later. The report concluded that treatment of the fibrovascular margin often resulted in haemorrhage, and for this reason, it is no longer recommended practice. </P>
<P>4. Mousel et al 1985 (<LINK REF="STD-Mousel-1985" TYPE="STUDY">Mousel 1985</LINK>): Excluded from analysis<BR/>Six eyes of six infants with bilateral ROP were treated with cryotherapy at two centres. One eye was assigned to cryoablation and the fellow eye received no therapy. In five of the six cases, treatment allocation was non-random. The authors performed all the eye examinations and outcome assessments.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>
<LINK REF="STD-CRYO_x002d_ROP-1988" TYPE="STUDY">CRYO-ROP 1988</LINK>
<BR/>Concealment of randomisation - yes<BR/>Masked intervention - not possible<BR/>Complete follow-up - all randomised accounted for, 7% lost at 5½ years.<BR/>Masked outcome assessment - yes</P>
<P>Tasman 1985<BR/>Concealment of randomisation - cannot tell, probably not<BR/>Masked intervention - not possible<BR/>Complete follow up - yes (although excluded infants not described)<BR/>Masked outcome assessment - cannot tell, probably not</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Two randomised cohorts were combined and analysed with the CRYO-ROP study contributing the majority of the data (87%). Both studies used cryoablation. In eyes (265 total) with threshold ROP, cryotherapy reduced the incidence of unfavorable retinal structure at less than 12 months after randomisation from 47.9% to 28.1% (absolute risk reduction of 19.8% [95% CI 27.9 - 11.8%]), RRR of 41%. Therefore the number of eyes with threshold ROP needed to treat (NNT) to avoid one unfavorable outcome is five. </P>
<P>For outcomes in early childhood (5½ years) only data from the CRYO-ROP study were used. At 5½ years, cryotherapy reduced the incidence of unfavorable retinal structure from 44.3% to 26.3% (absolute risk reduction 18% [95% CI 27.0 - 9.1%]), RRR of 41%, and unfavorable visual acuity from 63% to 50.6% (absolute risk reduction of 12.2% [95% CI 21.2 - 3.1]), RRR of 19%. Therefore the number of eyes with threshold ROP needed to treat to prevent one early childhood unfavorable retinal structural event (NNT) is 5.5 . Similarly, the number needed to treat to prevent one unfavorable visual acuity event (NNT) in early childhood is 8. Visual field data from 78 infants at 5 of the 23 centres in the CRYO-ROP cohort and from 14 of 28 infants in Tasman's study was combined to provide information on visual field outcome in premature infants with ROP treated with cryotherapy. In the CRYO-ROP cohort the white sphere used for testing fields was 6 degrees in diameter whereas the Goldmann stimulus used in Tasman's cohort was approximately 3 degrees (25mm2 ). Analysis of the combined data show that cryotherapy reduced the visual field in sighted eyes from 58.2°± 14.5° in controls with ROP to 51.3° ± 11.8° in the treated group with ROP.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Data from published randomised studies provides strong evidence that peripheral retinal ablation reduces the incidence of adverse visual outcome in premature infants with threshold ROP. Specifically, peripheral retinal ablation reduces the risk of adverse structural outcome at 12 months and at 5½ years. Further, this reduction in adverse structural outcome is reflected in a corresponding reduction in adverse acuity in the same infants. The advantage of retinal ablation in these eyes outweighs short term morbidity associated with the therapy. This includes an increase incidence of apnoea and bradycardia both during the procedure and in the following 1 to 3 days.</P>
<P>Interpretation of the data on visual fields is a little more complex. Although the studies tested visual fields differently, both are kinetic perimetry procedures and as such they are similar in methodology. In addition, although only a quarter of the inception cohort from the CRYO-ROP randomised study are reported, the cohort includes infants from five of twenty-three participating centres. Clearly, it is difficult to make generalisations from these data particularly as they do not include all of the original cohort. However, these data were included in the review to provide an insight into a possible adverse risk in the sighted eyes of infants treated with cryotherapy for threshold ROP. Further data from the whole cohort will be required before the significance of visual field reduction after peripheral retinal ablation is known. It is important to note that, compared to normal, eyes with ROP that spontaneously recovered also had a reduction in visual field.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There is good evidence that peripheral retinal ablation reduces the incidence of adverse ophthalmic outcomes, both structural and functional, in premature infants with threshold retinopathy of prematurity.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Further research is needed before the significance of visual field defects in premature infants with ROP is known and whether the advantage conferred by peripheral ablation will persist into adult life.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors thank Dr B. Lemyre and Dr P. Hamr for assistance with the translation of foreign language articles and Scott Shutts and Audra Boyer for extraction, copying and management of the numerous references. This work was supported in part by the NIH, National Eye Institute (DLP).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS/>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-04-07 16:08:28 -0400" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-04-07 16:07:42 -0400" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-04-07 15:54:43 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-CRYO_x002d_ROP-1988" MODIFIED="2008-04-07 15:52:48 -0400" MODIFIED_BY="[Empty name]" NAME="CRYO-ROP 1988" YEAR="1988">
<REFERENCE MODIFIED="2008-04-07 15:50:31 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cryotherapy for Retinopathy of Prematurity Cooperative Group</AU>
<TI>Multicenter trial of cryotherapy for retinopathy of prematurity. 3 1/2-year outcome--structure and function</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1993</YR>
<VL>111</VL>
<PG>339-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-04-07 15:50:50 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cryotherapy for Retinopathy of Prematurity Cooperative Group</AU>
<TI>Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome--structure and function</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1990</YR>
<VL>108</VL>
<PG>1408-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-04-07 15:51:03 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cryotherapy for Retinopathy of Prematurity Cooperative Group</AU>
<TI>Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1988</YR>
<VL>106</VL>
<PG>471-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-04-07 15:51:18 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cryotherapy for Retinopathy of Prematurity Cooperative Group</AU>
<TI>Multicenter trial of cryotherapy for retinopathy of prematurity. Snellen visual acuity and structural outcome at 5 1/2 years after randomization</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1996</YR>
<VL>114</VL>
<PG>417-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-04-07 15:51:31 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cryotherapy for Retinopathy of Prematurity Cooperative Group</AU>
<TI>Multicenter trial of cryotherapy for retinopathy of prematurity. Three-month outcome</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1990</YR>
<VL>108</VL>
<PG>195-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cryotherapy for Retinopathy of Prematurity Cooperative Group</AU>
<TI>Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results</TI>
<SO>Pediatrics</SO>
<YR>1988</YR>
<VL>81</VL>
<PG>697-706</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-04-07 15:52:05 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Dobson V, Quinn GE, Abramov I, Hardy RJ, Tung B, Siatkowski RM, Phelps DL. Color vision measured with pseudoisochromatic plates at five-and-a-half years in eyes of children from the CRYO-ROP study. Investigative Ophthalmology &amp;amp; Visual Science 1996;37:2467-2474.&lt;/p&gt;" NOTES_MODIFIED="2008-04-07 15:52:05 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dobson V, Quinn GE, Abramov I, Hardy RJ, Tung B, Siatkowski RM, Phelps DL</AU>
<TI>Color vision measured with pseudoisochromatic plates at five-and-a-half years in eyes of children from the CRYO-ROP study</TI>
<SO>Investigative Ophthalmology and Visual Science</SO>
<YR>1996</YR>
<VL>37</VL>
<PG>2467-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-04-07 15:52:30 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gilbert WS, Quinn GE, Dobson V, Reynolds J, Hardy RJ, Palmer EA</AU>
<TI>Multicenter Trial of Cryotherapy for Retinopathy of Prematurity Cooperative Group. Partial retinal detachment at 3 months after threshold retinopathy of prematurity. Long-term structural and functional outcome</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1996</YR>
<VL>114</VL>
<PG>1085-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-04-07 15:52:42 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palmer EA</AU>
<TI>Results of U.S. randomized clinical trial of cryotherapy for ROP (CRYO-ROP)</TI>
<SO>Documenta Ophthalmologica</SO>
<YR>1990</YR>
<VL>74</VL>
<PG>245-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-04-07 15:52:48 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quinn GE, Dobson V, Hardy RJ, Tung B, Phelps DL, Palmer EA</AU>
<TI>Visual fields measured with double-arc perimetry in eyes with threshold retinopathy of prematurity from the cryotherapy for retinopathy of prematurity trial</TI>
<SO>Ophthalmology</SO>
<YR>1996</YR>
<VL>103</VL>
<PG>1432-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tasman--1985" MODIFIED="2008-04-07 15:54:43 -0400" MODIFIED_BY="[Empty name]" NAME="Tasman  1985" YEAR="1987">
<REFERENCE MODIFIED="2008-04-07 15:53:03 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quinn GE, Miller DL, Evans JA, Tasman WE, McNamara JA, Schaffer DB</AU>
<TI>Measurement of Goldmann visual fields in older children who received cryotherapy as infants for threshold retinopathy of prematurity</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1996</YR>
<VL>114</VL>
<PG>425-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-04-07 15:53:34 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Tasman W, Benson WE, Brown GC, Diamond G, Naidoff M, Quinn GE, Schaffer DB. Cryotherapy in active retinopathy of prematurity. International Ophthalmology 1987;10:107.&lt;/p&gt;" NOTES_MODIFIED="2008-04-07 15:53:34 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tasman W, Benson WE, Brown GC, Diamond G, Naidoff M, Quinn GE, Schaffer DB</AU>
<TI>Cryotherapy in active retinopathy of prematurity</TI>
<SO>International Ophthalmology</SO>
<YR>1987</YR>
<VL>10</VL>
<PG>107</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-04-07 15:53:57 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Tasman W, Brown GC, Naidoff M, Schaffer DB, Benson W, Quinn GE, Diamond G. Cryotherapy for active retinopathy of prematurity. Graefes Archive for Clinical &amp;amp; Experimental Ophthalmology 1987;225:3-4.&lt;/p&gt;" NOTES_MODIFIED="2008-04-07 15:53:57 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tasman W, Brown GC, Naidoff M, Schaffer DB, Benson W, Quinn GE, Diamond G</AU>
<TI>Cryotherapy for active retinopathy of prematurity</TI>
<SO>Graefes Archive for Clinical and Experimental Ophthalmology</SO>
<YR>1987</YR>
<VL>225</VL>
<PG>3-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-04-07 15:54:05 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tasman W, Brown GC, Schaffer DB, Quinn GE, Naidoff M, Benson WE, Diamond G</AU>
<TI>Cryotherapy for active retinopathy of prematurity</TI>
<SO>Ophthalmology</SO>
<YR>1986</YR>
<VL>93</VL>
<PG>580-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-04-07 15:54:35 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Tasman W. A pilot study on cryotherapy and active retinopathy of prematurity. Graefes Archive for Clinical &amp;amp; Experimental Ophthalmology 1986;224:201-202.&lt;/p&gt;" NOTES_MODIFIED="2008-04-07 15:54:35 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tasman W</AU>
<TI>A pilot study on cryotherapy and active retinopathy of prematurity</TI>
<SO>Graefes Archive for Clinical and Experimental Ophthalmology</SO>
<YR>1986</YR>
<VL>224</VL>
<PG>201-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-04-07 15:54:43 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tasman W</AU>
<TI>Management of retinopathy of prematurity</TI>
<SO>Ophthalmology</SO>
<YR>1985</YR>
<VL>92</VL>
<PG>995-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-04-07 16:06:28 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ben_x002d_Sira--1986" MODIFIED="2008-04-07 15:54:51 -0400" MODIFIED_BY="[Empty name]" NAME="Ben-Sira  1986" YEAR="1986">
<REFERENCE MODIFIED="2008-04-07 15:54:51 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ben-Sira I, Nissenkorn I, Weinberger D, Shohat M, Kremer I, Krikler R, Reisner SH</AU>
<TI>Long-term results of cryotherapy for active stages of retinopathy of prematurity</TI>
<SO>Ophthalmology</SO>
<YR>1986</YR>
<VL>93</VL>
<PG>1423-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bert--1981" MODIFIED="2008-04-07 15:55:20 -0400" MODIFIED_BY="[Empty name]" NAME="Bert  1981" YEAR="1981">
<REFERENCE MODIFIED="2008-04-07 15:55:20 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Bert MD, Friedman MW, Ballard R. Combined cryosurgery and scleral buckling in acute proliferative retrolental fibroplasia. Journal of Pediatric Ophthalmology &amp;amp; Strabismus 1981;18:9-12.&lt;/p&gt;" NOTES_MODIFIED="2008-04-07 15:55:20 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bert MD, Friedman MW, Ballard R</AU>
<TI>Combined cryosurgery and scleral buckling in acute proliferative retrolental fibroplasia</TI>
<SO>Journal of Pediatric Ophthalmology and Strabismus</SO>
<YR>1981</YR>
<VL>18</VL>
<PG>9-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davis-1990" MODIFIED="2008-04-07 15:55:44 -0400" MODIFIED_BY="[Empty name]" NAME="Davis 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-04-07 15:55:44 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Davies PA. Retinopathy of prematurity [editorial]. Developmental Medicine &amp;amp; Child Neurology 1990;32:377-378.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-04-07 15:55:44 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davies PA</AU>
<TI>Retinopathy of prematurity [editorial]</TI>
<SO>Developmental Medicine and Child Neurology</SO>
<YR>1990</YR>
<VL>32</VL>
<PG>377-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fritch-1983" MODIFIED="2008-04-07 15:56:08 -0400" MODIFIED_BY="[Empty name]" NAME="Fritch 1983" YEAR="1983">
<REFERENCE MODIFIED="2008-04-07 15:56:08 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Fritch CD. Early management of retinal problems associated with prematurity: cryothermy treatment. Annals of Ophthalmology 1983;15:565-566.&lt;/p&gt;" NOTES_MODIFIED="2008-04-07 15:56:08 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fritch CD</AU>
<TI>Early management of retinal problems associated with prematurity: cryothermy treatment</TI>
<SO>Annals of Ophthalmology</SO>
<YR>1983</YR>
<VL>15</VL>
<PG>565-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerhard-1986" MODIFIED="2008-04-07 15:58:02 -0400" MODIFIED_BY="[Empty name]" NAME="Gerhard 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-04-07 15:58:02 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Gerhard JP. [Prevention of retinopathy of prematurity]. [Review] [French]. Journal Francais d Ophtalmologie 1986;9:583-596.&lt;/p&gt;" NOTES_MODIFIED="2008-04-07 15:58:02 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerhard JP</AU>
<TI>Prevention of retinopathy of prematurity [Review] [French]</TI>
<SO>Journal Français d'ophtalmologie</SO>
<YR>1986</YR>
<VL>9</VL>
<PG>583-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goggin-1993" MODIFIED="2008-04-07 15:59:14 -0400" MODIFIED_BY="[Empty name]" NAME="Goggin 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-04-07 15:58:35 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goggin M, O'Keefe M</AU>
<TI>Diode laser for retinopathy of prematurity--early outcome</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1993</YR>
<VL>77</VL>
<PG>559-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-04-07 15:59:14 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;O'Keefe M, Goggin M, Algawi K. Laser therapy for retinopathy of prematurity [letter; comment]. Arch Ophthalmol 113:137;1995.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-04-07 15:59:14 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Keefe M, Goggin M, Algawi K</AU>
<TI>Laser therapy for retinopathy of prematurity [letter; comment]</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1995</YR>
<VL>113</VL>
<PG>137</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guilbert-1986" MODIFIED="2008-04-07 15:59:22 -0400" MODIFIED_BY="[Empty name]" NAME="Guilbert 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-04-07 15:59:22 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Guilbert F, Castier P, Madelain F, Amber A, and Leguern P. [Current status of retinopathy of premature infants in northern France]. [French]. Bulletin des Societes d Ophtalmologie de France 1986;86:869-873.&lt;/p&gt;" NOTES_MODIFIED="2008-04-07 15:59:22 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guilbert F, Castier P, Madelain F, Amber A, Leguern P</AU>
<TI>Current status of retinopathy of premature infants in northern France [French]</TI>
<SO>Bulletin des Societes d Ophtalmologie de France</SO>
<YR>1986</YR>
<VL>86</VL>
<PG>869-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harris-1976" MODIFIED="2008-04-07 15:59:48 -0400" MODIFIED_BY="[Empty name]" NAME="Harris 1976" YEAR="1976">
<REFERENCE MODIFIED="2008-04-07 15:59:48 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Harris GS, McCormick AQ. The prophylactic treatment of retrolental fibroplasia. Modern Problems in Ophthalmology 1977;18:364-367.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-04-07 15:59:48 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harris GS, McCormick AQ</AU>
<TI>The prophylactic treatment of retrolental fibroplasia</TI>
<SO>Modern Problems in Ophthalmology</SO>
<YR>1977</YR>
<VL>18</VL>
<PG>364-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-04-07 15:45:30 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Harris GS. Retinopathy of prematurity and retinal detachment. Canadian Journal of Ophthalmology 11:21-25, 1976.&lt;/p&gt;" NOTES_MODIFIED="2008-04-07 15:45:30 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harris GS</AU>
<TI>Retinopathy of prematurity and retinal detachment</TI>
<YR>1976</YR>
<PG>21-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hindle-1990" MODIFIED="2008-04-07 16:00:20 -0400" MODIFIED_BY="[Empty name]" NAME="Hindle 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-04-07 16:00:20 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hindle NW</AU>
<TI>Cryotherapy for retinopathy of prematurity: none, one, or both eyes [letter; comment]</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1990</YR>
<VL>108</VL>
<PG>1375-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hindle NW</AU>
<TI>Cryotherapy in infants with retinopathy of prematurity [letter; comment]</TI>
<SO>JAMA</SO>
<YR>1990</YR>
<VL>263</VL>
<PG>2052</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holmstrom-1993" MODIFIED="2008-04-07 16:00:36 -0400" MODIFIED_BY="[Empty name]" NAME="Holmstrom 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-04-07 16:00:36 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holmstrom G</AU>
<TI>Retinopathy of prematurity [editorial] [see comments]</TI>
<SO>BMJ</SO>
<YR>1993</YR>
<VL>307</VL>
<PG>694-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iverson-1991" MODIFIED="2008-04-07 16:01:03 -0400" MODIFIED_BY="[Empty name]" NAME="Iverson 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-04-07 16:01:03 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iverson DA, Trese MT, Orgel IK, Williams GA</AU>
<TI>Laser photocoagulation for threshold retinopathy of prematurity [letter]</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1991</YR>
<VL>109</VL>
<PG>1342-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalina-1990" MODIFIED="2008-04-07 16:01:44 -0400" MODIFIED_BY="[Empty name]" NAME="Kalina 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-04-07 16:01:44 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalina RE</AU>
<TI>Update on retinopathy of prematurity</TI>
<SO>Western Medicine - the Medical Journal of the West</SO>
<YR>1990</YR>
<VL>153</VL>
<PG>188-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keith-1989" MODIFIED="2008-04-07 16:02:15 -0400" MODIFIED_BY="[Empty name]" NAME="Keith 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-04-07 16:02:15 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Keith CG, Doyle LW, Kitchen WH. Cryotherapy for retinopathy of prematurity [letter]. Arch Ophthalmol 107:1989;315-316.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-04-07 16:02:15 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keith CG, Doyle LW, Kitchen WH</AU>
<TI>Cryotherapy for retinopathy of prematurity [letter]</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1989</YR>
<VL>107</VL>
<PG>315-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-L_x0027_Esperance-1969" MODIFIED="2008-04-07 16:02:24 -0400" MODIFIED_BY="[Empty name]" NAME="L'Esperance 1969" YEAR="1969">
<REFERENCE MODIFIED="2008-04-07 16:02:24 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>L'Esperance FAJ</AU>
<TI>The treatment of ophthalmic vascular disease by argon laser photocoagulation</TI>
<SO>Transactions - American Academy of Ophthalmology &amp; Otolaryngology</SO>
<YR>1969</YR>
<VL>73</VL>
<PG>1077-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Landers-1990" MODIFIED="2008-04-07 16:02:43 -0400" MODIFIED_BY="[Empty name]" NAME="Landers 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-04-07 16:02:43 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Landers MB, Semple HC, Ruben JB, Serdahl C</AU>
<TI>Argon laser photocoagulation for advanced retinopathy of prematurity</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1990</YR>
<VL>110</VL>
<PG>429-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laser-Group-1994" MODIFIED="2008-04-07 16:03:13 -0400" MODIFIED_BY="[Empty name]" NAME="Laser Group 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-04-07 16:03:13 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clarkson JG, Capone JA, Sternberg JP, Repka MX, Gilbert W, Chase C, Trese M, Palmer EA, Brown GC, McNamara JA, Quinn GE, Schaffer DB, Tasman W, Vander JF, Landers III MB, Spencer R, Hardy RJ</AU>
<TI>Laser therapy for retinopathy of prematurity</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1994</YR>
<VL>112</VL>
<PG>154-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mousel-1985" MODIFIED="2008-04-07 16:03:38 -0400" MODIFIED_BY="[Empty name]" NAME="Mousel 1985" YEAR="1985">
<REFERENCE MODIFIED="2008-04-07 16:03:27 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mousel DK, Hoyt CS</AU>
<TI>Cryotherapy for retinopathy of prematurity</TI>
<SO>Ophthalmology</SO>
<YR>1980</YR>
<VL>87</VL>
<PG>1121-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-04-07 16:03:38 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Mousel DK. Cryotherapy for retinopathy of prematurity. A personal retrospective. Ophthalmology 92:375-378, 1985.&lt;/p&gt;" NOTES_MODIFIED="2008-04-07 16:03:38 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mousel DK</AU>
<TI>Cryotherapy for retinopathy of prematurity. A personal retrospective</TI>
<SO>Ophthalmology</SO>
<YR>1985</YR>
<VL>92</VL>
<PG>375-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nagata-1988" MODIFIED="2008-04-07 16:03:47 -0400" MODIFIED_BY="[Empty name]" NAME="Nagata 1988" YEAR="1988">
<REFERENCE MODIFIED="2008-04-07 16:03:47 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Nagata M, Terauchi H, Takeuchi A, Eguchi K, Tada K, Fujioka K, Oshima T, Majima A, Kato T, Ichikawa K, et al. [Multicenter prospective studies of retinopathy of prematurity. I. Incidence and results of treatment]. [Japanese]. Nippon Ganka Gakkai Zasshi - Acta Societatis Ophthalmologicae Japonicae 1988;92:646-657.&lt;/p&gt;" NOTES_MODIFIED="2008-04-07 16:03:47 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nagata M, Terauchi H, Takeuchi A, Eguchi K, Tada K, Fujioka K, Oshima T, Majima A, Kato T, Ichikawa K, et al</AU>
<TI>Multicenter prospective studies of retinopathy of prematurity. I. Incidence and results of treatment [Japanese]</TI>
<SO>Nippon Ganka Gakkai Zasshi - Acta Societatis Ophthalmologicae Japonicae</SO>
<YR>1988</YR>
<VL>92</VL>
<PG>646-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NH-Cryo-1986" MODIFIED="2008-04-07 16:03:58 -0400" MODIFIED_BY="[Empty name]" NAME="NH Cryo 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-04-07 16:03:58 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palmer EA, Phelps DL</AU>
<TI>Multicenter trial of cryotherapy for retinopathy of prematurity</TI>
<SO>Pediatrics</SO>
<YR>1986</YR>
<VL>77</VL>
<PG>428-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nissenkorn-1984" MODIFIED="2008-04-07 16:04:46 -0400" MODIFIED_BY="[Empty name]" NAME="Nissenkorn 1984" YEAR="1984">
<REFERENCE MODIFIED="2008-04-07 16:04:21 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nissenkorn I, Kremer I, Ben-Sira I, Cohen S, Garner A</AU>
<TI>A clinicopathological case of retinopathy of prematurity (ROP) treated by peripheral cryopexy</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1984</YR>
<VL>68</VL>
<PG>36-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-04-07 16:04:46 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Nissenkorn I, Kremer I, Cohen S, Garner A, Ben-Sira I. Cryotreatment of retinopathy of prematurity [letter]. Br J Ophthalmol 68:686-687, 1984.&lt;/p&gt;" NOTES_MODIFIED="2008-04-07 16:04:46 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nissenkorn I, Kremer I, Cohen S, Garner A, Ben-Sira I</AU>
<TI>Cryotreatment of retinopathy of prematurity [letter]</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1984</YR>
<VL>68</VL>
<PG>686-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patz-1971" MODIFIED="2008-04-07 16:04:55 -0400" MODIFIED_BY="[Empty name]" NAME="Patz 1971" YEAR="1971">
<REFERENCE MODIFIED="2008-04-07 16:04:55 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patz A, Maumenee AE, Ryan SJ</AU>
<TI>Argon laser photocoagulation. Advantages and limitations</TI>
<SO>Transactions - American Academy of Ophthalmology &amp; Otolaryngology</SO>
<YR>1971</YR>
<VL>75</VL>
<PG>569-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schechter-1993" MODIFIED="2008-04-07 16:05:23 -0400" MODIFIED_BY="[Empty name]" NAME="Schechter 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-04-07 16:05:23 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schechter RJ</AU>
<TI>Laser treatment of retinopathy of prematurity [letter; comment]</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1993</YR>
<VL>111</VL>
<PG>730-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silverman-1986" MODIFIED="2008-04-07 16:05:41 -0400" MODIFIED_BY="[Empty name]" NAME="Silverman 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-04-07 16:05:41 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silverman WA</AU>
<TI>Epoche in retinopathy of prematurity</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1986</YR>
<VL>61</VL>
<PG>522-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stefansson--1983" MODIFIED="2008-04-07 16:06:04 -0400" MODIFIED_BY="[Empty name]" NAME="Stefansson  1983" YEAR="1983">
<REFERENCE MODIFIED="2008-04-07 16:06:04 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stefansson E, Landers MB, Wolbarsht ML</AU>
<TI>Oxygenation and vasodilatation in relation to diabetic and other proliferate retinopathies</TI>
<SO>Ophthalmic Surgery</SO>
<YR>1983</YR>
<VL>14</VL>
<PG>209-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Topilow--1990" MODIFIED="2008-04-07 16:06:28 -0400" MODIFIED_BY="[Empty name]" NAME="Topilow  1990" YEAR="1990">
<REFERENCE MODIFIED="2008-04-07 16:06:28 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Topilow HW, Ackerman AL</AU>
<TI>Cryotherapy for stage 3+ retinopathy of prematurity [letter; comment]</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1990</YR>
<VL>108</VL>
<PG>15-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2008-04-07 16:07:42 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Al_x0027_banskii-1983" MODIFIED="2008-04-07 16:06:36 -0400" MODIFIED_BY="[Empty name]" NAME="Al'banskii 1983" YEAR="1983">
<REFERENCE MODIFIED="2008-04-07 16:06:36 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Al'banskii VG, Medvedev AN. [Retrolental fibroplasia]. [Review] [RUSSIAN]. Vestnik Oftalmologii 1983;65-69.&lt;/p&gt;" NOTES_MODIFIED="2008-04-07 16:06:36 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Al'banskii VG, Medvedev AN</AU>
<TI>Retrolental fibroplasia [Review] [Russian]</TI>
<SO>Vestnik Oftalmologii</SO>
<YR>1983</YR>
<PG>65-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Helm-1982" MODIFIED="2008-04-07 16:06:46 -0400" MODIFIED_BY="[Empty name]" NAME="Helm 1982" YEAR="1982">
<REFERENCE MODIFIED="2008-04-07 16:06:46 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Helm W, Matzen C. [Symptomatic treatment of retinopathy in premature infants by photocoagulation]. [Polish]. Klinika Oczna 1982;84:303-304.&lt;/p&gt;" NOTES_MODIFIED="2008-04-07 16:06:46 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Helm W, Matzen C</AU>
<TI>Symptomatic treatment of retinopathy in premature infants by photocoagulation [Polish]</TI>
<SO>Klinika Oczna</SO>
<YR>1982</YR>
<VL>84</VL>
<PG>303-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Majima---1976" MODIFIED="2008-04-07 16:07:30 -0400" MODIFIED_BY="[Empty name]" NAME="Majima   1976" YEAR="1976">
<REFERENCE MODIFIED="2008-04-07 16:07:30 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Majima A, Takahashi M, Hibino Y. Clinical observations of photocoagulation on retinopathy of prematurity. Japanese Journal of Clinical Ophthalmology 1976;30:93-97.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-04-07 16:07:30 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Majima A, Takahashi M, Hibino Y</AU>
<TI>Clinical observations of photocoagulation on retinopathy of prematurity</TI>
<SO>Japanese Journal of Clinical Ophthalmology</SO>
<YR>1976</YR>
<VL>30</VL>
<PG>93-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prost-1984" MODIFIED="2008-04-07 16:07:42 -0400" MODIFIED_BY="[Empty name]" NAME="Prost 1984" YEAR="1984">
<REFERENCE MODIFIED="2008-04-07 16:07:42 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Prost M. [Present therapeutic possibilities in retrolental fibroplasia]. [Polish]. Klinika Oczna 1984;86:309-311.&lt;/p&gt;" NOTES_MODIFIED="2008-04-07 16:07:42 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prost M</AU>
<TI>Present therapeutic possibilities in retrolental fibroplasia [Polish]</TI>
<SO>Klinika Oczna</SO>
<YR>1984</YR>
<VL>86</VL>
<PG>309-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-04-07 16:08:28 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-04-07 16:08:28 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Aiello-1996" MODIFIED="2008-04-07 16:08:10 -0400" MODIFIED_BY="[Empty name]" NAME="Aiello 1996" TYPE="JOURNAL_ARTICLE">
<AU>Aiello LP</AU>
<TI>Vascular endothelial growth factor and the eye - past, present, and future</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1996</YR>
<VL>114</VL>
<PG>1252-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICCROP-1994" MODIFIED="2008-04-07 16:08:20 -0400" MODIFIED_BY="[Empty name]" NAME="ICCROP 1994" TYPE="JOURNAL_ARTICLE">
<AU>International Committee for the Classification of Retinopathy of Prematurity</AU>
<TI>An international classification of retinopathy of prematurity</TI>
<SO>Pediatrics</SO>
<YR>1984</YR>
<VL>74</VL>
<PG>127-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Provis-1997" MODIFIED="2008-04-07 16:08:28 -0400" MODIFIED_BY="[Empty name]" NAME="Provis 1997" TYPE="JOURNAL_ARTICLE">
<AU>Provis JM, Leech, J, Diaz CM, Penfold PL, Stone J, and Keshet E</AU>
<TI>Development of the human retinal vasculature - cellular relations and VEGF expression</TI>
<SO>Experimental Eye Research</SO>
<YR>1997</YR>
<VL>65</VL>
<PG>555-68</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-12 12:52:08 -0500" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-CRYO_x002d_ROP-1988">
<CHAR_METHODS>
<P>Randomized controlled trial of peripheral ablation of avascular retina with cryotherapy</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>291 infants with birth weight &lt;1251grams, confirmed defined severity of ROP ("threshold") by certified examiners. Infants with congenital anomalies, or retinal detachment in one eye were not eligble for enrollment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cryotherapy to avascular retina in one randomly selected eye if bilateral. Random assignment to treatment or control if only one eye. No infant received cryotherapy to both eyes.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Early: (up to one year) Retinal detachment, retinal folds involving the macula, or retrolental tissue or mass were unfavorable outcomes. Later outcomes included visual acuity, color vision, peripheral fields, myopia, and other visual outcomes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multiple manuscripts over several years of accumulating data</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tasman--1985">
<CHAR_METHODS>
<P>Controlled trial of treatment to one eye, allocation uncertain</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>28 infants with bilateral stage 3 ROP with plus disease in Zone I or II.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cryotherapy to the avascular retina in one eye.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Regression of ROP vs retinal detachment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Allocation of eyes was apparently not random. However, treatment was not clearly based on the relative severity of the ROP.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Ben_x002d_Sira--1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case matched controls, not concurrent.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bert--1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series, no controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Davis-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Narrative review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fritch-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series, no controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gerhard-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Narrative review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goggin-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Laser compared to cryotherapy, no untreated controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Guilbert-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Observational study, no control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harris-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment was not limited to the avascular retina. Unable to assess outcomes from report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hindle-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Letter, no new data reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Holmstrom-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Narrative review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iverson-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Laser vs cryotherapy, no untreated controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kalina-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Commentary, no data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Keith-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Letter, contains case series data, no controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-L_x0027_Esperance-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review of techniques, single case described, no controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Landers-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series, no controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Laser-Group-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>No control group. Meta-analysis of laser vs cryotherapy with original data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mousel-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Six infants with bilateral ROP. One eye treated with cryotherapy; however, selection was based on severity. Treatment was applied to both the avascular retina and the line of demarcation. Ablation of the vessels at the transition is no longer recommended.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nagata-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Natural history study, all severe ROP treated with photocoagulation or cyrotherapy. No controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-NH-Cryo-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomized subjects, no control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nissenkorn-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case report, no controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Patz-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Narrative review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schechter-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Letter, no data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Silverman-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Narrative review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stefansson--1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Narrative review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Topilow--1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>No control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2008-11-12 12:52:08 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2008-11-12 12:51:37 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Al_x0027_banskii-1983">
<CHAR_METHODS MODIFIED="2008-11-12 12:51:26 -0500" MODIFIED_BY="[Empty name]">
<P>Not known</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-12 12:51:33 -0500" MODIFIED_BY="[Empty name]">
<P>Not known</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-12 12:51:35 -0500" MODIFIED_BY="[Empty name]">
<P>Not known</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-12 12:51:37 -0500" MODIFIED_BY="[Empty name]">
<P>Not known</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2008-11-12 12:51:48 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Helm-1982">
<CHAR_METHODS MODIFIED="2008-11-12 12:51:41 -0500" MODIFIED_BY="[Empty name]">
<P>Not known</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-12 12:51:43 -0500" MODIFIED_BY="[Empty name]">
<P>Not known</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-12 12:51:46 -0500" MODIFIED_BY="[Empty name]">
<P>Not known</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-12 12:51:48 -0500" MODIFIED_BY="[Empty name]">
<P>Not known</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2008-11-12 12:51:57 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Majima---1976">
<CHAR_METHODS MODIFIED="2008-11-12 12:51:50 -0500" MODIFIED_BY="[Empty name]">
<P>Not known</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-12 12:51:53 -0500" MODIFIED_BY="[Empty name]">
<P>Not known</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-12 12:51:55 -0500" MODIFIED_BY="[Empty name]">
<P>Not known</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-12 12:51:57 -0500" MODIFIED_BY="[Empty name]">
<P>Not known</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2008-11-12 12:52:08 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prost-1984">
<CHAR_METHODS MODIFIED="2008-11-12 12:52:00 -0500" MODIFIED_BY="[Empty name]">
<P>Not known</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-12 12:52:04 -0500" MODIFIED_BY="[Empty name]">
<P>Not known</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-12 12:52:06 -0500" MODIFIED_BY="[Empty name]">
<P>Not known</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-12 12:52:08 -0500" MODIFIED_BY="[Empty name]">
<P>Not known</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-CRYO_x002d_ROP-1988">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tasman--1985">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Peripheral retinal ablation vs control</NAME>
<DICH_OUTCOME CHI2="1.4327124194336802" CI_END="0.7374516283260659" CI_START="0.46583655126035783" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5861159640043511" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="127" I2="30.20232208252386" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.13226646109899157" LOG_CI_START="-0.3317664381115637" LOG_EFFECT_SIZE="-0.23201644960527762" METHOD="MH" NO="1" P_CHI2="0.23132253964221994" P_Q="0.0" P_Z="5.143780434534176E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="267" TOTAL_2="265" WEIGHT="100.0" Z="4.558836465615628">
<NAME>Early unfavorable retinal structure (&lt;12 mo)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7842741535157733" CI_START="0.4844904393487791" EFFECT_SIZE="0.6164197670473821" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="111" LOG_CI_END="-0.10553209733268529" LOG_CI_START="-0.31471478864218655" LOG_EFFECT_SIZE="-0.21012344298743593" ORDER="80" O_E="0.0" SE="0.12287494834622292" STUDY_ID="STD-CRYO_x002d_ROP-1988" TOTAL_1="239" TOTAL_2="237" VAR="0.01509825293108695" WEIGHT="87.44767116062893"/>
<DICH_DATA CI_END="0.8167641132780115" CI_START="0.1721733334188911" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" LOG_CI_END="-0.08790335239485025" LOG_CI_START="-0.7640341121497121" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="81" O_E="0.0" SE="0.3971625551812447" STUDY_ID="STD-Tasman--1985" TOTAL_1="28" TOTAL_2="28" VAR="0.15773809523809523" WEIGHT="12.552328839371064"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.1797989509133116" CI_END="0.8352264235191582" CI_START="0.6324657662994051" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.72680954863331" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="239" I2="76.0754043018865" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.07819577463032112" LOG_CI_START="-0.19896297672862776" LOG_EFFECT_SIZE="-0.13857937567947443" METHOD="MH" NO="2" P_CHI2="0.04090868439636497" P_Q="0.0" P_Z="6.856820351127308E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="435" TOTAL_2="434" WEIGHT="200.0" Z="4.498085251833855">
<NAME>Early childhood retinal outcomes (5.5 yr)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7773281278023744" CI_START="0.4523019694126874" DF="0.0" EFFECT_SIZE="0.5929477574667865" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="94" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-0.10939561696151172" LOG_CI_START="-0.3445715212454573" LOG_EFFECT_SIZE="-0.22698356910348452" NO="1" P_CHI2="1.0" P_Z="1.547144442465949E-4" STUDIES="1" TAU2="0.0" TOTAL_1="213" TOTAL_2="212" WEIGHT="100.00000000000001" Z="3.783377569056152">
<NAME>Unfavorable retinal structure</NAME>
<DICH_DATA CI_END="0.7773281278023745" CI_START="0.45230196941268735" EFFECT_SIZE="0.5929477574667865" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="94" LOG_CI_END="-0.10939561696151166" LOG_CI_START="-0.3445715212454574" LOG_EFFECT_SIZE="-0.22698356910348452" ORDER="82" O_E="0.0" SE="0.1381434903158909" STUDY_ID="STD-CRYO_x002d_ROP-1988" TOTAL_1="213" TOTAL_2="212" VAR="0.01908362391665664" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9514989252626298" CI_START="0.6960167769366439" DF="0.0" EFFECT_SIZE="0.8137931034482758" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="145" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-0.021591697921125714" LOG_CI_START="-0.1573802919365733" LOG_EFFECT_SIZE="-0.08948599492884952" NO="2" P_CHI2="1.0" P_Z="0.009786858711314829" STUDIES="1" TAU2="0.0" TOTAL_1="222" TOTAL_2="222" WEIGHT="100.0" Z="2.5832703910510526">
<NAME>Unfavorable visual acuity</NAME>
<DICH_DATA CI_END="0.9514989252626298" CI_START="0.6960167769366439" EFFECT_SIZE="0.8137931034482758" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="145" LOG_CI_END="-0.021591697921125714" LOG_CI_START="-0.1573802919365733" LOG_EFFECT_SIZE="-0.08948599492884952" ORDER="83" O_E="0.0" SE="0.07976289228905482" STUDY_ID="STD-CRYO_x002d_ROP-1988" TOTAL_1="222" TOTAL_2="222" VAR="0.006362118986315362" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.3893285306166977" CI_END="-4.141995501554623" CI_START="-12.30752826854964" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.224761885052132" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="0.5326529292879756" P_Q="1.0" P_Z="7.868796153789483E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="43" UNITS="" WEIGHT="100.0" Z="3.9483613711716994">
<NAME>Extent of visual fields (degrees)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.0703086496438754" CI_START="-12.729691350356136" EFFECT_SIZE="-6.900000000000006" ESTIMABLE="YES" MEAN_1="51.3" MEAN_2="58.2" ORDER="2" SD_1="11.8" SD_2="14.5" SE="2.974386976668955" STUDY_ID="STD-CRYO_x002d_ROP-1988" TOTAL_1="44" TOTAL_2="37" WEIGHT="49.047619805687376"/>
<CONT_DATA CI_END="-3.780312623775986" CI_START="-15.219687376224014" EFFECT_SIZE="-9.5" ESTIMABLE="YES" MEAN_1="49.3" MEAN_2="58.8" ORDER="85" SD_1="3.9" SD_2="6.3" SE="2.918261468751558" STUDY_ID="STD-Tasman--1985" TOTAL_1="8" TOTAL_2="6" WEIGHT="50.952380194312624"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>